Equine Sarcoid: What the Research Says
Evidence from 24 peer-reviewed studies
What Professionals Should Know
- •Currently, no single sarcoid treatment can be recommended as superior based on available evidence—treatment selection should consider individual case factors and owner preferences rather than relying on evidence-based guidelines
- •Ensure histopathological confirmation of sarcoid diagnosis before committing to treatment, as diagnostic inconsistency is common in the literature and affects outcome interpretation
- •Prepare clients to expect transient local inflammation as a normal response to most sarcoid treatments; this is not necessarily a sign of treatment failure
- •Nearly half of equine sarcoids recur at the surgical site after excision; histological assessment of inflammation status may help predict recurrence risk
- •Presence of superficial inflammation in excised sarcoid tissue is a favorable prognostic indicator for reduced recurrence at the original site
- •Owners should be counseled that approximately one-third of horses develop new sarcoids at distant anatomical sites regardless of local recurrence status
- •Blood microRNA testing cannot yet predict whether a young horse with existing sarcoids will improve or worsen, limiting its clinical utility for prognosis
- •Sex-specific microRNA panels may eventually help identify young male horses at high risk of developing sarcoids in the future, enabling early monitoring
- •Breed and sex must be accounted for when developing and interpreting equine biomarker tests, as these factors significantly affect microRNA expression independent of disease status
- •PCR screening for BPV1/2 DNA in tissue samples provides a reliable diagnostic tool to confirm equine sarcoid diagnosis rapidly and objectively
- •Healthy, sarcoid-free equids do not carry detectable BPV1/2 DNA, so the infection appears to require active disease rather than chronic latency
- •The presence of BPV DNA in some wound healing and dermatitis cases suggests monitoring for potential viral involvement in problematic skin healing
- •BPV DNA load quantification could help stratify sarcoid cases by severity to guide treatment decisions
- •Understanding the viral load-disease severity relationship may improve prognosis assessment for affected horses
- •Intralesional viral analysis offers a potential objective parameter for monitoring disease progression and treatment response
- •Surgical excision with wider margins (≥12mm) is more likely to remove all BPV DNA-containing tissue and reduce recurrence risk
- •Histologically normal-appearing skin immediately adjacent to sarcoids frequently harbors BPV DNA; standard surgical margins may be insufficient to eliminate the virus
- •PCR analysis of surgical margins could help predict recurrence risk and guide decisions about additional treatments or closer monitoring
- •Autologous tumor implantation is a technically simple option with 50% success rate; consider for cases with low tumor burden and facial/limb locations rather than body sarcoids
- •Prior treatment failures predict poor outcomes (77% less likely to improve), so this technique may not be suitable for refractory cases
- •Combined antineoplastic therapy does not improve results over implantation alone, so can simplify treatment protocols and reduce client costs
- •Include sarcoid in the differential diagnosis for oral masses in horses, despite its rarity in this location
- •Consider oral trauma history when evaluating horses with intraoral masses, as it may predispose to sarcoid development
- •Incomplete excision of an oral sarcoid may not necessarily result in recurrence, though longer-term follow-up data are needed
- •CPT1A overexpression in sarcoids reveals a metabolic adaptation strategy allowing tumor cells to thrive in hypoxic conditions—this may inform future targeted treatment approaches beyond current surgical and immunological interventions
- •Understanding that sarcoid fibroblasts preferentially use fatty acid oxidation for energy could eventually lead to metabolic-based therapies, though this research is still at the basic science stage
- •This molecular finding does not change current diagnostic or management protocols for sarcoids but strengthens the rationale for ongoing research into metabolic vulnerabilities of equine tumors
- •Equine sarcoids may result from repeated cross-species transmission of BPV from cattle rather than horse-specific viral variants, suggesting epidemiological control should focus on cattle-horse contact management
- •The absence of horse-adapted BPV variants explains why equine sarcoids persist and recur unlike regressive BPV papillomas in cattle—horses lack biological adaptation to the virus
- •Veterinarians managing horses with sarcoids should consider herd epidemiology and potential cattle exposure when developing treatment and prevention strategies
- •Sarcoids depend on angiogenesis (new blood vessel formation) mediated by VEGF, which may explain their aggressive growth and recurrence after surgery
- •Anti-angiogenic therapeutic approaches targeting VEGF pathways could represent a novel treatment strategy to reduce sarcoid recurrence rates beyond surgical intervention alone
- •Understanding the molecular drivers of sarcoid development may inform better treatment planning and client counseling regarding prognosis and recurrence risk
- •Early intervention and prevention of mechanical injury to skin may reduce sarcoid development risk in predisposed horses, as wound healing dysregulation appears central to pathogenesis
- •Understanding the role of chronic inflammation and matrix remodeling in sarcoids could inform future treatment strategies targeting MMPs or collagen dysregulation
- •Maintain good immune status and wound care practices, as immunosuppression combined with BPV infection appears to promote sarcoid transformation
- •Sarcoid aggressiveness and recurrence risk may be linked to MMP-1 expression, which could guide future therapeutic targeting beyond current surgical approaches
- •All clinical types of sarcoids show similar invasive mechanisms at the cellular level, suggesting uniform biological behaviour despite different surface morphologies
- •Understanding MMP involvement in sarcoid pathogenesis may lead to adjunctive treatments that address the underlying invasive process and reduce recurrence rates
- •Understanding MGMT's role in sarcoid development may eventually lead to more effective therapeutic targets for this common equine skin tumour
- •Epigenetic mechanisms appear to play a regulatory role in sarcoid formation, suggesting potential for targeted molecular interventions
- •This molecular research provides foundational knowledge for developing improved treatment options beyond current limited therapies
- •Understanding BPV E5-induced molecular pathways in sarcoids may inform development of targeted therapeutic interventions beyond current surgical and immunological approaches
- •PDGFbeta-r activation represents a potential diagnostic marker or therapeutic target for equine sarcoid management
- •This molecular characterization establishes equine sarcoid as a valuable in-vivo model for studying BPV-induced carcinogenesis mechanisms
- •Sarcoids are common, difficult-to-treat skin tumors that frequently recur—early identification and intervention are important before lesions progress to more aggressive forms
- •Location and size of sarcoids matter: even benign-appearing lesions can compromise function, rideability, or welfare depending on anatomical position
- •BPV involvement means sarcoids are infectious tumors; consider isolation/hygiene protocols and avoid trauma to lesions, as injury may accelerate progression
- •NVX-207 shows promise as a potential topical treatment for equine sarcoid and melanoma, but in vivo clinical trials are essential before any practical application
- •The mechanism of action is apoptosis with minimal necrosis, which may reduce inflammation compared to other topical therapies
- •This is early-stage research; expect several years of development before availability to practitioners
- •Stable fly control may be a useful management strategy to reduce potential BPV transmission risk in equine operations, particularly where sarcoid-affected horses are present
- •Isolated equids developing sarcoids without direct contact to affected animals may warrant investigation of stable fly populations as a possible exposure route
- •Further research is needed before firm clinical recommendations can be made; this study demonstrates possibility but not confirmed transmission under field conditions
- •ISH assay is a reliable diagnostic tool for confirming BPV involvement in suspected sarcoids, improving diagnostic certainty over histology alone
- •Wide distribution of viral nucleic acid throughout sarcoid lesions suggests systemic viral involvement rather than localized infection, which may inform treatment strategy selection
- •The consistent detection of BPV in sarcoids but not controls strengthens the causal link between BPV and equine sarcoids, supporting the viral origin of these neoplasms
- •This improved cell enrichment protocol may facilitate development of dendritic cell-based immunotherapy for equine sarcoid treatment
- •The technique optimizes starting material quality for therapeutic cell generation, potentially improving clinical outcomes when dendritic cell therapies are implemented
- •Veterinarians considering cellular immunotherapy approaches should be aware that reliable CD14+ enrichment methodology is foundational to efficacy
- •Do not rely on routine histology alone for skin tumors resembling schwannomas; many may actually be atypical sarcoids with different treatment implications
- •Request BPV PCR and S-100 immunohistochemistry when pathology reports suggest schwannoma or nerve sheath tumors, as misdiagnosis can lead to inappropriate management strategies
- •Understanding the myofibroblastic nature of these atypical sarcoids may improve targeting of future treatment options beyond current surgical and topical approaches
- •Topical aciclovir cream offers a non-invasive treatment option for equine sarcoids, with two-thirds achieving complete resolution when applied daily for 2-6 months
- •Thicker, more established sarcoids may require surgical debulking prior to aciclovir therapy to optimize treatment outcomes
- •Consider aciclovir as first-line therapy for early-stage sarcoids to avoid surgical intervention, or combine with surgery for advanced cases
- •Understanding papillomavirus as a confirmed cause of equine sarcoids may inform prevention strategies and client education about viral transmission
- •Recognition of PV-associated skin lesions in horses allows for earlier intervention before progression to neoplastic disease
- •Cross-species evidence of PV-induced neoplasia suggests monitoring and biosecurity measures may be warranted in multi-species facilities
- •Understanding the molecular basis of equine sarcoids may inform development of more effective treatment strategies to reduce high post-treatment recurrence rates
- •Identification of deregulated genes involved in cell motility and invasion could help explain why sarcoids are difficult to treat despite being benign tumors
- •Further research on these genetic markers may eventually lead to improved diagnostic or prognostic tools for equine sarcoid management
Key Research Findings
Sarcoid regression rates ranged from 28% to 100% at individual lesion level and 9% to 100% at whole horse level across included studies
Only 60% of included papers confirmed case definition via histopathology in all lesions, indicating inconsistent diagnostic standards
Significant heterogeneity between the 10 included studies prevented quantitative synthesis and most papers had critical or concerning risk of bias
Transient local inflammation was common following most treatment strategies, with few other adverse events reported
Sarcoid recurrence at the surgical site occurred in 46.9% of 64 horses (30 cases) following excision
New sarcoids developed at distant sites in 32.8% of horses (21 cases)
Superficial inflammation on histopathology was associated with significantly reduced recurrence risk (adjusted odds ratio 0.32, P = 0.04)
The inflammatory process may provide a protective mechanism against sarcoid recurrence
Eca-miR-127 discriminated between sarcoid-affected and tumor-free horses in whole blood samples
Eca-miR-125a-5p and eca-miR-432 showed potential to predict sarcoid development in young male horses over 5-12 year follow-up period
No microRNA expression variation distinguished between horses with sarcoid regression versus progression
Sex and breed significantly influenced expression levels of five and two microRNAs respectively, confounding biomarker discovery
BPV1/2 E5 DNA was detected in 100% (130/130) of confirmed sarcoids but 0% (0/137) of tumour-free equids
BPV1/2 DNA was present in 63/120 suspected sarcoids and 13/70 nonsarcoid lesions, suggesting possible co-induction of other skin disorders
Six different BPV1 E5 variants were identified among positive samples
Evidence Base
Treatment of equine sarcoids: A systematic review.
Offer Katie S, Dixon Claire E, Sutton David G M (2024) — Equine veterinary journal
Histological evidence of superficial inflammation is associated with lower recurrence of equine sarcoids following surgical removal: A follow-up study of 106 tumours in 64 horses.
Curnow B, Rich A F, Ireland J et al. (2023) — Veterinary journal (London, England : 1997)
Diagnostic and prognostic potential of eight whole blood microRNAs for equine sarcoid disease.
Cosandey Jeanne, Hamza Eman, Gerber Vinzenz et al. (2021) — PloS one
No evidence of bovine papillomavirus type 1 or 2 infection in healthy equids.
Pratscher B, Hainisch E K, Sykora S et al. (2019) — Equine veterinary journal
Intralesional bovine papillomavirus DNA loads reflect severity of equine sarcoid disease.
Haralambus R, Burgstaller J, Klukowska-Rötzler J et al. (2010) — Equine veterinary journal
Polymerase chain reaction analysis of the surgical margins of equine sarcoids for bovine papilloma virus DNA.
Martens A, De Moor A, Demeulemeester J et al. (2001) — Veterinary surgery : VS
Outcomes following autologous tumor tissue implantation with or without concurrent antineoplastic therapies in the treatment of sarcoids in 50 equids.
Smith Caitlin H, Stewart Holly L, Stefanovski Darko et al. (2025) — Frontiers in veterinary science
Sarcoid within the oral cavity of a horse.
Munday John S, Lewis Michelle C, Leyland Margaret H (2024) — Journal of equine veterinary science
Overexpression of the key metabolic protein Carnitine Palmitoyl Transferase 1A (CPT1A) in equine sarcoid.
Martano Manuela, Power Karen, Cuccaro Bianca et al. (2024) — Journal of equine veterinary science
Complete genomic characterization of bovine papillomavirus type 1 and 2 strains infers ongoing cross-species transmission between cattle and horses.
Gysens L, Vanmechelen B, Maes P et al. (2023) — Veterinary journal (London, England : 1997)
Expression of vascular endothelial growth factor (VEGF) in equine sarcoid.
Martano Manuela, Power Karen, Restucci Brunella et al. (2018) — BMC veterinary research
Extracellular matrix remodeling in equine sarcoid: an immunohistochemical and molecular study.
Martano Manuela, Corteggio Annunziata, Restucci Brunella et al. (2016) — BMC veterinary research
Equine sarcoid: In situ demonstration of matrix metalloproteinase expression.
Mosseri S, Hetzel U, Hahn Shelley et al. (2014) — Veterinary journal (London, England : 1997)
O(6)-methylguanine-DNA methyltransferase in equine sarcoids: molecular and epigenetic analysis.
Altamura Gennaro, Strazzullo Maria, Corteggio Annunziata et al. (2012) — BMC veterinary research
Activated platelet-derived growth factor beta receptor expression, PI3K-AKT pathway molecular analysis, and transforming signals in equine sarcoids.
Borzacchiello G, Mogavero S, De Vita G et al. (2009) — Veterinary pathology
Equine Sarcoids-Causes, Molecular Changes, and Clinicopathologic Features: A Review.
Ogłuszka Magdalena, Starzyński Rafał Radosław, Pierzchała Mariusz et al. (2021) — Veterinary pathology
In vitro assessment of triterpenoids NVX-207 and betulinyl-bis-sulfamate as a topical treatment for equine skin cancer.
Weber Lisa Annabel, Funtan Anne, Paschke Reinhard et al. (2020) — PloS one
The possible role of Stomoxys calcitrans in equine sarcoid transmission.
Haspeslagh M, Vlaminck L, Martens A (2018) — Veterinary journal (London, England : 1997)
Localization of Bovine Papillomavirus Nucleic Acid in Equine Sarcoids.
Gaynor A M, Zhu K W, Dela Cruz F N et al. (2016) — Veterinary pathology
Enhanced protocol for CD14+ cell enrichment from equine peripheral blood via anti-human CD14 mAb and automated magnetic activated cell sorting.
Durán M C, Willenbrock S, Carlson R et al. (2013) — Equine veterinary journal
Show 4 more references
Molecular and immunohistochemical distinction of equine sarcoid from schwannoma.
Bogaert L, Heerden M Van, Cock H E V De et al. (2011) — Veterinary pathology
Successful treatment of equine sarcoids by topical aciclovir application.
Stadler S, Kainzbauer C, Haralambus R et al. (2011) — The Veterinary record
Papillomavirus-associated cutaneous neoplasia in mammals.
Munday J S, Kiupel M (2010) — Veterinary pathology
Mobility and Invasion Related Gene Expression Patterns in Equine Sarcoid.
Podstawski Przemysław, Witarski Wojciech, Szmatoła Tomasz et al. (2020) — Animals : an open access journal from MDPI